Zipalertinib

Delivery:
oral
MOA:

Tyrosine Kinase Inhibitor of EGFR exon 20 insertion mutations

Indication:

Non-Small Cell Lung Cancer 2L+

Phase 1/2 REZILIENT1 (Cullinan) Study (Pivotal Trial)

Phase 2 REZILIENT2 Study